Clinical Study on Shugan Tiaoshen Acupuncture Intervention for Patients with Generalized Anxiety Disorder Under Epidemic Situation

注册号:

Registration number:

ITMCTR2200006843

最近更新日期:

Date of Last Refreshed on:

2022-12-01

注册时间:

Date of Registration:

2022-12-01

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

疏肝调神针法干预疫情下广泛性焦虑症患者的临床研究

Public title:

Clinical Study on Shugan Tiaoshen Acupuncture Intervention for Patients with Generalized Anxiety Disorder Under Epidemic Situation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

疏肝调神针法干预疫情下广泛性焦虑症患者的临床研究

Scientific title:

Clinical Study on Shugan Tiaoshen Acupuncture Intervention for Patients with Generalized Anxiety Disorder Under Epidemic Situation

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200066310 ; ChiMCTR2200006843

申请注册联系人:

周夏芸

研究负责人:

周夏芸

Applicant:

zhou xiayun

Study leader:

zhou xiayun

申请注册联系人电话:

Applicant telephone:

19874205056

研究负责人电话:

Study leader's telephone:

19874205056

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

0755-27806622

申请注册联系人电子邮件:

Applicant E-mail:

carman2021@163.com

研究负责人电子邮件:

Study leader's E-mail:

carman2021@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

深圳市宝安区裕安二路25号

研究负责人通讯地址:

深圳市宝安区裕安二路25号

Applicant address:

25 Yu 'an 2nd Road, Bao 'an District, Shenzhen

Study leader's address:

25 Yu 'an 2nd Road, Bao 'an District, Shenzhen

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

深圳市宝安区中医院

Applicant's institution:

Shenzhen Bao’an Traditional Chinese Medicine Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

KY-2022-034-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

深圳市宝安区中医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Shenzhen Bao 'an Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022/11/28 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

深圳市宝安区中医院

Primary sponsor:

Shenzhen Bao’an Traditional Chinese Medicine Hospital

研究实施负责(组长)单位地址:

深圳市宝安区裕安二路25号

Primary sponsor's address:

25 Yu 'an 2nd Road, Bao 'an District, Shenzhen

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong province

City:

单位(医院):

深圳市宝安区中医院

具体地址:

深圳市宝安区裕安二路25号

Institution
hospital:

Shenzhen Bao’an Traditional Chinese Medicine Hospital

Address:

25 Yu 'an 2nd Road, Bao 'an District, Shenzhen

经费或物资来源:

深圳市科技创新委员会课题立项资助

Source(s) of funding:

Supported by the project of Shenzhen Science and Technology Innovation Commission

研究疾病:

广泛性焦虑症

研究疾病代码:

Target disease:

Generalized anxiety disorder

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

评价疏肝调神针法治疗疫情下广泛性焦虑症的有效性及安全性,形成针灸干预的有效治疗方案

Objectives of Study:

To evaluate the efficacy and safety of acupuncture for soothing liver and regulating mind in treating generalized anxiety disorder under epidemic situation, and to form an effective therapeutic schedule for acupuncture intervention

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合上述广泛性焦虑症的中西医诊断标准,并于新冠疫情背景下确诊者; (2)汉密尔顿焦虑量表 (HAMA) 14项测定≥14分且<29分者; (3)年龄≥18岁,≤65岁; (4)近三周内未接受过药物、物理或心理治疗者,或病情稳定者; 签署知情同意书,自愿参加本项研究者。

Inclusion criteria

( 1 ) Patients who met the above diagnostic criteria of generalized anxiety disorder in Chinese and Western medicine and were diagnosed in the context of the new coronavirus epidemic ; ( 2 ) Hamilton Anxiety Scale ( HAMA ) 14 determination ≥ 14 points and < 29 points ; ( 3 ) Age ≥ 18 years, ≤ 65 years ; ( 4 ) those who have not received medication, physical or psychological treatment in the past three weeks, or those in stable condition ; signed informed consent and volunteered to participate in this study.

排除标准:

(1)不符合纳入标准的患者 ; (2)既往有脑外伤、癫痫病史,或伴有肝肾功不全,有金属植入物或合并心脑血管、肝、肾等严重的躯体器质性疾病的患者; (3)患有其他能够表现焦虑症状的精神分裂症、双相障碍或其他精神障碍类疾病、躯体疾病的患者; (4)既往及当前有自伤自杀计划或行为、精神病性症状者或酒精、药物滥用或成瘾后戒断引起焦虑者; (5)依从性可能较差或畏惧针灸者; (6)妊娠及哺乳期妇女。

Exclusion criteria:

( 1 ) Patients who do not meet the inclusion criteria ; ( 2 ) patients with a history of brain trauma, epilepsy, or accompanied by liver and kidney dysfunction, metal implants or severe physical organic diseases such as cardiovascular, cerebrovascular, liver and kidney ; ( 3 ) Patients with other anxiety symptoms of schizophrenia, bipolar disorder or other mental disorders, physical illness ; ( 4 ) Patients with previous or current suicide plan or behavior, psychotic symptoms or anxiety caused by alcohol, drug abuse or withdrawal after addiction ; ( 5 ) Patients with poor compliance or fear of acupuncture ; ( 6 ) Pregnant and lactating women.

研究实施时间:

Study execute time:

From 2022-12-02

To      2023-12-25

征募观察对象时间:

Recruiting time:

From 2022-12-02

To      2023-09-12

干预措施:

Interventions:

组别:

治疗组

样本量:

66

Group:

Treatment group

Sample size:

干预措施:

针刺加常规西药

干预措施代码:

Intervention:

Acupuncture plus conventional western medicine

Intervention code:

组别:

对照组

样本量:

66

Group:

Control group

Sample size:

干预措施:

假针刺加常规西药

干预措施代码:

Intervention:

Sham acupuncture plus conventional western medicine

Intervention code:

样本总量 Total sample size : 132

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong province

City:

单位(医院):

深圳市宝安区中医院

单位级别:

三级甲等

Institution/hospital:

Shenzhen Bao’an Traditional Chinese Medicine Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

相关量表评估(汉密尔顿焦虑量表、状态焦虑-特质焦虑问卷、生活事件量表、创伤后应激障碍自评量表)

指标类型:

主要指标

Outcome:

Related scale assessment ( Hamilton anxiety scale, state anxiety-trait anxiety questionnaire, life event scale, post-traumatic stress disorder self-rating scale )

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候积分

指标类型:

次要指标

Outcome:

chinese medicine syndrome scores

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医疗效评估

指标类型:

主要指标

Outcome:

Efficacy Evaluation of Traditional Chinese Medicine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用简单随机化方法,应用SPSS软件设计程序生成随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

Using Simple Randomization Method and SPSS Software Design Program to Generate Random Number Table

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan 平台:http://www.medresman.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan platform:http://www.medresman.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Excel保存原始记录、病例记录表等数据,ResMan数据库进行管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Excel to save the original records, case records and other data, ResMan database management

数据管理委员会:

Data Managemen Committee:

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above